- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06428955
Evaluation of a Monofocal Intraocular Lens (PRECISE)
May 20, 2024 updated by: Carl Zeiss Meditec AG
Prospective Multicenter Evaluation of the Visual Performance of a Non-constant Aberration Correcting Aspheric Monofocal Intraocular Lens (Precise Study))
The aim of this study is to investigate the 3-month visual performance of the CT LUCIA 621P IOL, a hydrophobic aspheric monofocal IOL with a non-constant aspheric optic profile in adult patients 50 years of age or older who are undergoing cataract surgery.
Study Overview
Study Type
Interventional
Enrollment (Estimated)
44
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Grant Sharpe
- Phone Number: +447918937014
- Email: grant.sharpe@zeiss.com
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Be at least 50 years of age or older, male or female, of any race or ethnicity.
- Presenting for uncomplicated bilateral cataract surgery for age-related cataract.
- Planned bilateral cataract extraction with posterior chamber IOL implantation, via phacoemulsification with or without femtosecond laser assisted cataract surgery (FLACS).
- Bilateral implantation of a CT LUCIA 621P IOL with a dioptric power between +10.00 D and +30.00 D and a target postoperative refraction of emmetropia (0.00 ±0.50 D).
- Clear intraocular media other than cataract (i.e. no hyphema, vitreous hemorrhage)
- No visual acuity limiting pathologies other than cataract. Best corrected postoperative visual acuity potential of 20/25 or better in both eyes as estimated by potential acuity meter or surgeon estimation.
- Provide written informed consent and a signed HIPPA form.
- Availability, willingness, ability, and sufficient cognitive awareness to comply with study examination procedures and the schedule for study visits and evaluations.
Exclusion Criteria:
- Corneal Astigmatism of >1.0 D.
- Planned monocular cataract extraction.
- Visual field loss which has an impact on visual acuity.
- Subjects with intraoperative surgical complications in whom a CT LUCIA 621P IOL cannot be implanted.
- History of acute or chronic disease, pathology, illness, or ocular trauma that would, in the surgeon's opinion, confound results (e.g., corneal pathology, keratoconus, strabismus, uncontrolled glaucoma)
- History of Glaucoma, macular degeneration, cystoid macular edema, proliferative diabetic retinopathy, amblyopia, etc.
- Previous intraocular or corneal surgery, including all forms of refractive surgery that might confound the outcome of the investigation or increase the risk to the subject
- Previous anterior or posterior chamber surgery other than peripheral retinal barrier laser, SLT/ALT (e.g., vitrectomy, laser iridotomy)
- Pupil abnormalities (non-reactive, tonic pupils, abnormally shaped pupils or pupils that do not dilate under mesopic/scotopic conditions).
- Capsular or zonular abnormalities or other conditions that increase the risk of zonular rupture during cataract extraction procedure and/or may affect the postoperative centration or tilt of the lens
- Use of a systemic or ocular medication that might affect vision and confound the outcome or increase the risk to the subject in the opinion of the investigator such as tamsulosin hydrochloride (Flomax) or other medications with similar side effects (floppy iris syndrome)
- Cycloplegic pupil diameter <6.0 mm or the presence of ocular implants that limit pupil diameter (malyugin rings; iris prosthesis).
- Usage of contact lenses during study participation
- Pregnant, lactating during the course of the investigation, or has another condition with associated fluctuation of hormones that could lead to refractive changes
- Presence or history or any other condition or finding that, in the investigator's opinion, makes the subject unsuitable as a candidate for study participation, may increase the operative risk or may confound the outcome of the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Bilateral implantation of investigational device
Monofocal IOL
|
The device under investigation, CT LUCIA 621P IOL (Carl Zeiss Meditec, Jena, Germany) is a posterior chamber intraocular lens which is indicated for aphakia after surgical extraction of the cataractous natural lens.
It is a monofocal aspheric IOL made of hydrophobic material and coated with heparin.
The modified C-loop haptic is step-vaulted.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Monocular best corrected distance visual acuity (CDVA)
Time Frame: Three (3) Months
|
The primary efficacy endpoint is the proportion of patients with monocular CDVA of 20/40 or better at three months
|
Three (3) Months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Binocular Corrected Distance Visual Acuity
Time Frame: Three (3) Months
|
Three (3) Months
|
|
Binocular Uncorrected Corrected Distance Visual Acuity
Time Frame: Three (3) Months
|
Three (3) Months
|
|
Monocular Uncorrected Visual Acuity
Time Frame: Three (3) Months
|
Three (3) Months
|
|
Monocular Distance Corrected Intermediate Visual Acuity
Time Frame: Three (3) Months
|
Three (3) Months
|
|
Monocular Uncorrected Intermediate Visual Acuity
Time Frame: Three (3) Months
|
Three (3) Months
|
|
Manifest Refraction Spherical Equivalent
Time Frame: Three (3) Months
|
Three (3) Months
|
|
Refractive Predictability
Time Frame: Three (3) Months
|
Manifest refraction will be evaluated at 1 and 3 months to determine refractive predictability.
The predicted refraction is the goal or target refraction from the IOLMaster IOL calculation and the observed refraction is the 3 Month postoperative Manifest Refraction Spherical Equivalent measurement.
|
Three (3) Months
|
Refractive Stability
Time Frame: Three (3) Months
|
Manifest refraction will be obtained at 1 and 3 months to evaluate whether refractive stability is achieved by 3 months.
Refractive stability will be evaluated at the 1 to 3 months interval as a parameter of interest to determine the proportion of eyes that achieve stability of manifest refraction.
|
Three (3) Months
|
Contrast Sensitivity - mesopic and photopic with and without glare
Time Frame: Three (3) Months
|
Three (3) Months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
May 1, 2024
Primary Completion (Estimated)
December 1, 2024
Study Completion (Estimated)
December 1, 2024
Study Registration Dates
First Submitted
May 15, 2024
First Submitted That Met QC Criteria
May 20, 2024
First Posted (Actual)
May 24, 2024
Study Record Updates
Last Update Posted (Actual)
May 24, 2024
Last Update Submitted That Met QC Criteria
May 20, 2024
Last Verified
May 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- GPAS-SAS-023-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
product manufactured in and exported from the U.S.
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cataract
-
Fundación Pública Andaluza para la Investigación...CompletedCataract | Cataract Mature | Cataract, Nuclear
-
Johannes Kepler University of LinzCompletedCataract Complicated | Cataract Complications OperationsAustria
-
Gemini Eye ClinicRecruitingBilateral Cataract | Unilateral CataractCzechia
-
Universitaire Ziekenhuizen KU LeuvenLaboratoires TheaRecruiting
-
Omer Othman AbdullahCompletedCongenital Cataract | Pediatric CataractIraq
-
Johannes Kepler University of LinzRecruitingAphakia | Secondary Cataract Surgery | Complicated Cataract SurgeryAustria
-
Yonsei UniversityCompletedCataract PatientsKorea, Republic of
-
Zhongshan Ophthalmic Center, Sun Yat-sen UniversityWest China Hospital; Beijing Tongren Hospital; Eye & ENT Hospital of Fudan University and other collaboratorsNot yet recruiting
-
Advanced Center for Eyecare GlobalNot yet recruiting
-
Vienna Institute for Research in Ocular SurgeryRecruiting
Clinical Trials on CT LUCIA 621P
-
Carl Zeiss Meditec AGCompleted
-
Cairo UniversityCompletedCentric Occlusion - Centric Relation Discrepancy (Disorder)Egypt
-
Northwell HealthToshiba America Medical Systems, Inc.Enrolling by invitationCoronary Artery Disease | Chest Pain | Acute Coronary Syndrome | Acute Myocardial InfarctionUnited States
-
The University of Texas Health Science Center at...Recruiting
-
UMC UtrechtDutch Heart FoundationUnknown
-
CelltrionCompleted
-
University of PittsburghTerminatedCarcinoma, Squamous Cell of Head and NeckUnited States
-
Rigshospitalet, DenmarkRecruitingCardiovascular Diseases | Coronary Artery Disease | Heart Failure | Stroke | Acute Myocardial Infarction | Chest SyndromeDenmark
-
Northwell HealthHeartFlow, Inc.CompletedAngina, Stable Chest Pain
-
Peter MacCallum Cancer Centre, AustraliaMelbourne Health; Westmead Hospital; Victorian Infectious Diseases Reference...CompletedAcute Myeloid Leukemia | Febrile Neutropenia | Acute Lymphoblastic Leukemia | Haematopoietic Stem Cell Transplant, Autologous | Haematopoietic Stem Cell Transplant, AllogeneicAustralia